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We established and validated an in toto method to perform TdT-mediated dUTP nick end labeling to study apoptosis in
human trabecular meshwork tissue obtained during trabeculectomy in glaucoma patients. In specimens from patients with
primary open-angle glaucoma and primary angle-closure glaucoma, we detected a tendency for more apoptotic cells to
accumulate in patients with primary open-angle glaucoma. The utility of this method to study apoptosis in the trabecular
meshwork is discussed, as well as its application as a tool in biologic samples.
Glaucoma is one of the most common causes of blindness
in the world and it is a progressive optic neuropathy that
provokes the loss of vision [1]. Glaucoma is characterized by
retinal ganglion cell death and cupping of the optic disc.
Primary open-angle glaucoma (POAG) is the most common
form of the disease and it is closely associated with an increase
in intraocular pressure (IOP) that results from an excessive
resistance to the outflow of the aqueous humor (AH) through
the conventional pathway [2]. This pathway involves both the
trabecular meshwork (TM) and Schlemm’s canal (SC); the
latter is responsible for the outflow of AH from the anterior
chamber to the venous system and it is situated at the angle
formed by the cornea and iris [3]. In the TM, arrays of collagen
beams are covered by endothelium-like cells and the space
between the beams is occupied by extracellular matrix (ECM).
The adjacent SC is a continuous endothelium-lined channel
that drains off AH into the bloodstream. The TM is anchored
by tendons of the longitudinal ciliary muscle (CM) and by
elastin fibers that connect it to the endothelium of the SC. Both
the TM and the longitudinal CM are actively involved in
regulating AH outflow and IOP. Indeed, these two structures
act as functional antagonists, since contraction of the CM
leads to a distension of the TM and the ensuing reduction in
outflow, whereas contraction of the TM produces the opposite
effect [4]. It is thought that the resistance to aqueous outflow
occurs at the junction where the TM meets the inner wall of
the SC, the juxtacanalicular region. Thus, the TM represents
the key region in the pathogenesis of glaucoma and it is a good
potential target for therapeutic interventions.
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The most characteristic structural alterations in the TM
of eyes with POAG involve the decrease in cellularity [5] and
an increase in the ECM, as well as the presence of “plaque
material” in the juxtacanalicular tissue. This “plaque material”
is an accumulation of banded fibrillar elements in which
different glycoproteins are embedded, and it derives from
thickened sheaths of elastic fibers [6]. These alterations in the
TM may produce critical changes in outflow resistance.
The loss of cells within the TM is more severe in POAG
patients than in normal age matched controls [5] and it is
thought to be an early event in POAG [7] whereby the TM
endothelial cell population diminishes with age [7,8]. At 20
years of age the entire meshwork has been estimated to contain
763,000 cells and this number decreases to 403,000 by the age
of 80, with a loss of approximately 6,000 cells per year [8].
The exact mechanism by which the cell population is reduced
in normal and glaucomatous human TM tissues is not known,
although several potential mechanisms have been suggested,
including wear-and tear, phagocytosis, cell migration, and cell
death [9]. Cell death may occur in different ways, including
apoptosis (type I), autophagy (type II), and necrosis (type III),
each of which is related with a particular series of events
[10]. Significantly, human TM cell lines, and ex vivo
dissected TM tissue obtained from normal donors, express
several modulators of apoptosis (Fas, Bcl-2, Bcl-Xl, Bax, and
caspases), and in addition, human TM cells can be stimulated
to undergo apoptosis via the Fas-FasL pathway [11].
However, to our knowledge apoptosis has not been detected
in the TM from glaucomatous patients.
DNA fragmentation is a typical feature of apoptotic cell
death and this process can be assessed via the activity of
multiple DNases, including DNase I that cleaves DNA leaving
3′-OH DNA ends. During apoptosis, caspase-activated DNase
(CAD) digests genomic DNA into oligonucleosomal
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fragments that are further cleaved by DNase I [12]. Thus,
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick end labeling(TUNEL) can take advantage of the increase
in free 3′-OH ends. The TdT enzyme can incorporate
fluorescein isothiocyanate (FITC) conjugated dUTP
nucleotides into these fragments, thus enabling the cells with
fragmented DNA to be visualized by fluorescence
microscopy. By applying TUNEL to whole specimens it is
possible to define rare cell death events, as shown previously
during early retinal development [13]. We established such a
method to evaluate whether or not apoptotic cell death might
contribute to the loss of cells within the TM. We successfully
identified apoptotic cells in human TM specimens obtained
during trabeculectomy. We examined patients with POAG as
well as those with PACG (primary angle-closure glaucoma),
the latter characterized by an obstruction to the outflow of AH
that produces an increase in IOP due to the anatomic
predisposition of the eye.
METHODS
Study population: Human tissue was handled in accordance
with the Helsinki Declaration and the Local Committee of
Ethics for experimentation with human tissues. Institutional
approval was obtained and all the patients enrolled in the study
provided their informed voluntary written consent. Seven
patients with POAG and four with PACG were included in
the study, in which only one eye was studied. The age of the
patients ranged from 55 to 85 years (mean age±SD, 71±12
years) and the disease duration ranged from 4 to 12 years
(Table 1 summarizes their demographic characteristics). The
patients were prospectively selected based on the following
criteria. The inclusion criteria were: glaucoma (POAG or
PACG), more than 50 years of age, access to at least three
reliable baseline preoperative visual fields, no retinal or
neurologic disease that may have affected the visual field, and
being treated with the same combination of drugs such as a
β-blocker (timolol maleate), a carbonic anhydrase inhibitor
(dorzolamide) and an α2 adrenergic agonist (brimonidine).
The exclusion criteria were: ocular disease other than
glaucoma, normal tension glaucoma, pseudoexfoliation or
pigmentary syndrome, previous eye surgery or laser
trabeculoplasty (argon laser trabeculoplasty or selective laser
trabeculoplasty), diabetes mellitus, uveitis, systemic
collagenopathy, and objective neurologic signs.
POAG was defined as the presence of a reproducible
visual field defect consistent with glaucoma and the
appearance of the optic disc, coupled with a pretreatment IOP
of at least 21 mmHg and an open angle with no signs of
secondary causes of glaucoma. The PACG diagnosis was
based on the same criteria except that the angle was occludable
before laser iridotomy with the posterior TM visible for less
than 90° of the angle circumference. IOP was determined
using the Goldmann applanation tonometer (GAT; Haag-
Streit, Koeniz, Switzerland).
Stratification of patients: Perimetry was performed during the
four week period before surgery (Octopus tG1; Interzeag AG,
Switzerland). We divided the patients into four groups based
on Mean Defect (MD) values: MD greater than −6 dB (mild
visual field loss), MD between −6 and −12 dB (moderate
visual field loss), MD between −13 dB and −20 dB (severe
visual field loss), and MD greater than −20 dB (terminal).
Collection of trabecular meshwork specimens: The
experimental protocol required the removal of TM specimens
during trabeculectomy. The surgical technique employed has
been described elsewhere [14], and it involved the use of a
large flap (scleral flap size: 8–10x5–6 mm, flap thickness: 2/3
scleral thickness; excised inner block size: 6–5x4 mm) that
enabled us to obtain a large specimen. The TM specimens
were obtained according to standard surgical procedures and
for all specimens, a 45° knife was used to cut a 6–5x4 mm
button of corneoscleral tissue. The TM was then dissected out
under a microscope, and the TM biopsies were snap-frozen in
liquid nitrogen and stored at −80 °C until they were assayed.
Detection of apoptosis: TUNEL was performed on whole TM
specimens to label fragmented DNA with FITC-dUTP based
on previous methods [13,15]. Briefly, frozen samples were
thawed on ice and fixed overnight in 4% paraformaldehyde
(w/v, Sigma, St. Louis, MO) prepared in 0.1 M phosphate
buffer (PB, pH 7.4). The TM tissue was permeabilised for 2
h at RT (changing the solution every 30 min) with 4% Triton
X-100 in PBS (w/v, Fluka, Buchs, Switzerland), it was mildly
digested for 15 min at 37 °C with 20 μg/ml proteinase K in
PBS (Promega, Madison, WI), and it was then processed for
TUNEL following the manufacturer’s instructions (Apoptosis
Detection System, Promega). At the end of the assay, the TM
tissue was counterstained with 4',6-diamidino-2-phenylindole
(DAPI), mounted with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA) and visualized on a
confocal microscope (LEICA DMRE2, Heidelberg,
Germany). The number of apoptotic cells was determined by
counting TUNEL positive cells on images representing the
maximal projection of confocal series under 10X and 20X
objectives.
RESULTS
Programmed cell death can be detected in the TM of
glaucomatous patients: TM samples processed for TUNEL
were counterstained with DAPI to visualize the limit of the
TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF THE PATIENTS ENROLLED IN THE STUDY.
Statistics POAG PACG
Number 7 4
mean age years (±SD) 78±8 71±12
IOP (mm Hg; mean±SD) 24.2±2.1 22.5±4
Abbreviations in the table are: POAG, primary open-angle
glaucoma; PACG, primary angle-closure glaucoma; and IOP,
intraocular pressure.
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TM, as well as the corneal and scleral surfaces (Figure 1A,B).
In addition, DAPI staining also enabled pyknotic and
condensed nuclei to be identified, morphological features of
programmed cell death. We found TUNEL positive cells in
the sclera (Figure 1C) and the cornea (data not shown) of all
specimens analyzed, indicating that programmed cell death
occurred in this tissue as described previously [16]. Indeed, in
8 of the 11 samples analyzed (72.7%) there were TUNEL
stained cells in the TM (Figure 1C). To ensure that the green
TUNEL staining corresponded to apoptotic nuclei we
captured the same confocal images in the green (TUNEL) and
blue (DAPI) channels (box in Figure 1C), confirming that the
TUNEL cells corresponded to those with pyknotic nuclei.
There is more cell death in the trabecular meshwork from
POAG patients than in that of PACG patients: We
successfully identified apoptotic cells in human TM
specimens obtained during trabeculectomy. Apoptotic cells
were scored in images representing the maximal projections
of the confocal series throughout the whole TM. Figure 2A
represents TUNEL positive cells identified in the TM of each
POAG and PACG patients against their correspondent visual
fields, expressed as MD values. The accumulated numbers
showed a clear tendency toward an increase in the number of
TUNEL positive cells in specimens collected from POAG
patients (Figure 2B) indicating a greater incidence of
apoptosis associated with this condition.
DISCUSSION
In this communication, we demonstrate that programmed cell
death occurs in the TM of POAG and PACG patients,
although the number of apoptotic cells may be higher in the
former condition. These observations were achieved by
developing a TUNEL method to stain the TM as a whole,
facilitating the visualization and scoring of the relatively low
number of apoptotic cells in this tissue.
Figure 1. TUNEL positive cells can be detected in TM samples from
glaucomatous patients. TM samples were stained with DAPI (A,B)
and by TUNEL (C). The DAPI staining allowed us to visualize the
structure of the specimen and to identify apoptotic nuclei both within
and outside of the TM. Dotted lines represent the limits of the TM
and the arrows indicate the presence of apoptotic cells in the TM and
sclera   of   a   POAG   patient.   The   inset   in C  shows a
pyknotic nucleus (visualized by DAPI blue staining) that is also
positive for TUNEL (green). Abbreviations in the figure are Co,
Cornea; TM, Trabecular Meshwork; Sc, Sclera. The scale bar is equal
to 250 μm in A and 150 μm in B and C.
Our observations may explain the loss of cells described
previously in POAG patients [5,7] and they suggest that
apoptosis could be one of the mechanisms by which trabecular
cells die in glaucoma. The differences observed in the number
of apoptotic cells between POAG and PACG patients are
unlikely to be due to the antiglaucoma treatment since these
patients all received the same type of anti-glaucoma
medication: β-blocker (timolol), carbonic anhydrase inhibitor
(dorzolamide) and α2 adrenergic agonist (brimonidine). While
it is possible that the antiglaucoma treatment may have
induced apoptosis in the TM of glaucomatous patients,
exposing cultured TM to anti-glaucoma drugs such as timolol
and pilocarpine does not induce apoptosis [17]. Moreover, the
effect of benzalkonium-preserved (BAC+) or preservative-
free (BAC-) antiglaucoma medication on the expression of
apoptotic markers in cultured human TM cells has also been
evaluated. At concentrations higher than those thought to be
found in the AH after instillation, unpreserved beta-blockers
(timolol and betaxolol) and prostaglandin (latanoprost) did
not exhibit any pro-apoptotic activity on TM cells in vitro
[18]. However, we cannot rule out that the long-term
administration of antiglaucoma treatment might contribute to
the apoptosis of TM cells.
The relationship between TM cell loss and the apoptosis
observed in POAG patients deserves further characterization,
as do the mechanisms underlying the apoptosis in the TM. It
has been suggested that intense phagocytic activity of
trabecular cells could lead to cell death [19]. Furthermore,
glaucoma itself could also produce apoptosis of TM cells
through mechanical stress [20] or through trabecular
hypoperfusion [21]. An increase in oxidative stress may also
contribute to cell loss or alterations in the functioning of TM
cells [22,23].
Finally, we have to mention two limitations of this study.
One is the absence of the control group since it is impossible
to obtain TM specimens from control subjects. The other one
is the small number of subjects included in each group due to
Figure 2. Scoring of TUNEL positive cells in the TM of POAG and
PACG patients. TUNEL-positive apoptotic cells were scored in
maximal projection images of confocal series taken under 10X and
20X objectives and represented as TUNEL-positive cells per area.
A: The values are represented individually and classified according
to the Mean Defect (MD) criterion and the type of glaucoma (PACG
or POAG). B: Values (mean±SD) grouped for PACG or POAG
patients.
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the difficulty of obtaining TM samples from glaucoma
patients which fulfill the strict inclusion and exclusion criteria.
Despite these restrictions the technique is still suitable to study
cell death in the TM and will enable us to more accurately
evaluate the different alternatives for the etiology of the
pathological stage, as well as of the effectivity of certain
therapeutic approaches. This method may also be applicable
to study apoptosis in other human tissues obtained by surgery.
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